We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Callisto Pharmaceuticals has begun a multicenter, open-label, dose-escalation Phase I clinical trial of L-Annamycin in children and young adults with refractory or relapsed acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML).
Manhattan Pharmaceuticals announced it has completed patient enrollment in its first Phase IIa, multicenter, international clinical study evaluating the safety and preliminary efficacy of oral oleoyl-estrone (OE) for the treatment of obesity.
UCB has announced key results from a Phase III study (RAPID 1) involving nearly 1,000 patients on Cimzia (certolizumab pegol), the first PEGylated, Fc-free anti-TNF intended for the treatment of moderate to severe rheumatoid arthritis (RA).
Join RxTrials Institute and FDAnews Tuesday, Feb. 27,
for "Clinical Trial Payment Forecasting: Preventing a Cash Flow Crunch." In this 90-minute interactive audioconference, Michael Jay, budget and contracts director for RxTrials, will show you, through two case studies, how to effectively analyze the true cost of conducting clinical trials. On Feb. 28, join FDAnews for "Patient Assistance Programs and Part D: Establishing and Ensuring Compliance with HHS." In this 90-minute audioconference with Q&A session, Michael D. Beauvais, an attorney with Ropes & Gray, will deliver the real-world knowledge pharma companies need to deploy a compliant patient assistance program.
Theravance announced that the FDA has accepted the company's new drug application (NDA) for its investigational antibiotic telavancin for treating complicated skin and skin structure infections (cSSSIs) caused by Gram-positive organisms, including methicillin-resistant Staphylococcus aureus.
Pharmacyclics announced it has received a refuse-to-file letter from the FDA for the company's new drug application (NDA) for Xcytrin for the treatment of non-small-cell lung cancer patients with brain metastases.